News
Objective The benefit of continuing 5-aminosalicylate (5-ASA) in patients with ulcerative colitis (UC) who initiate anti-tumour necrosis factor-alpha (anti-TNF) biologics is unknown. We aimed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback